• Top-level Domains: 
  BIOPHARMA.com
  BIOPHARMA.org
  and over 100 others

• BIOPHARMA®:  U.S. trademark for "providing information in the fields of biopharmaceuticals via electronic databases, Web sites and the Internet;" the only BIOPHARMA® trademark.  

Background:  'Biopharma(ceutical):'
1) within the industry, science, etc. often still retains its original/classic biotechnology-grounded definition involving pharmaceuticals manufactured using biotechnology (living organisms), with 'biopharma(ceutical)' a subset of 'pharma(ceutical).'
2) in the past decade with push from industry, "biopharma(ceutical)" has become (or soon enough will be) the preferred popular/common and industry's-own term for the global pharmaceutical industry and its products, particularly where desiring to project a positive image.  'Biopharma(ceutical)' is replacing 'pharma(ceutical)' in common and industry use, much as 'pharma(ceutical)' replaced use of 'drug' in the 1970s/80s.  Or the term sometimes refers more to or implies only innovative/R&D-intensive (bio)pharmaceuticals and companies, as often used by the largest R&D-intensive companies and their trade groups.  [This broad industry Pharma(ceutical) → Biopharma(ceutical) renaming/rebranding trend is nothing new.  See a related Nature Biotechnology article, "(Re)Defining Biopharmaceutical," I authored 13 years ago]. 

'Biopharma' is a >$1 trillion/year industry using the now predominant broad definition; and is a >$400 billion/year subset using the classic definition.  In the next few years, the 'Pharma(ceutical)' industry will genuinely become the 'Biopharma(ceutical)' industry as biopharmaceutical (using the classic biotech-grounded defintion) R&D and product revenue top that of chemically-derived/synthetic pharmaceuticals.  With this, 'biopharma(ceutical)' will come to fully replace 'pharma(ceutical)' in common usage; surely assisted by the global pharmaceutical industry, long publicly claiming to be 'biopharmaceutical.' 

Most of the world's leading (bio)pharmaceutical companies and trade groups have already switched to using 'biopharmaceutical' to refer to and (re)brand themselves, their products and the industry.  PhRMA has been prominently citing its members as and using the tagline "America's Biopharmaceutical Companies" now for >15 years; and "The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in Europe."  Along with the switch to using 'biopharma(ceutical),' 'pharma(ceutical)' and 'drug' are increasingly evoking negative perceptions and becoming legacy/dated, simply no longer used.  For example, just look at PhRMA's annual "flagship publication." 

As with "pharma," the word "biopharma" has universal recognition and is used as both as an adjective (e.g., biopharma R&D, products, companies, etc.) and a proper noun (e.g., "Biopharma," referring to the industry).  Google retrieved 43.6 million entries for the word "biopharma" (no truncation) and 143 million for "biopharma" (truncated) on Jan. 20 (these nos. vary daily).  There are >600 publicly traded companies in the U.S. with "biopharma" in their name (SEC); and a total of >2,000 "biopharma" companies in the U.S. and ~4,000 worldwide (D&B). There are >2,650 "biopharma" (no truncation) company entries in Cruchbase and >800 in LinkedIn.  Over 4,150 domain names contain, >1,100 names start with and >2,500 end with "biopharma." 

Utility:  Top-level domain and exact-match trademark ownership, a potent and rare combination, will provide your organization with exclusive and unbeatable "BIOPHARMA" Internet presence and branding opportunities!  How much is it worth to your organization to be recognized as a (or the) leading 'Biopharma' industry organization and/or be the top-level/first-used industry information source?  For example: 
a) Brand your Web site, company, trade group, products, technologies, services, information resources, etc. as "BIOPHARMA."  Your company could even become "Biopharma Inc." or "BIOPHARMA.com Inc.;"
b) Be the leading source for information and promote your image and views about the biopharmaceutical industry; its products, technologies, public affairs, etc.; and/or otherwise
c) Greatly improve the impact and cost-effectiveness of your public relations, marketing, advertising, lobbying, etc.  Such a prominent domain/trademark is its own perpetual advertising campaign.  The utility, impact, benefits and cost-effectiveness of a 'BIOPHARMA' domain/trademark will surely be much higher than your usual episodic and transitory advertising, marketing, public relations, lobbying, efforts.  And these invaluable IP-based opportunities come from just a one-time purchase and can remain yours forever! 

Value:  Besides already being an established brand, with much invested in this by the industry, increasing common use and continuing industry-wide rebranding as 'biopharma(ceutical)' will assure increasing value of this 'BIOPHARMA' IP for years to come!  Besides conveying a positive image associated with high-tech research, life-saving products, innovation, being 'bio(tech)', etc., unlike 'drug' and 'pharma(ceutical),' 'BIOPHARMA' is simply the best short term for the (bio)pharmaceutical industry and products.  Alternatives, e.g., "biopharm" and "biotech medicines," lack traction, have resisted catching on.  Self-promotion as "biopharma(ceutical)" by an increasing number of companies and trade associations worldwide alone provides this IP with $millions worth of related promotion annually. 

As intangible assets and corporate investments, the domains and trademark are solid and reliable.   Can you even imagine any loss of value or downsides to owning this IP?  Most likely you are already envisioning $millions/year in value and benefits use of this IP could provide your organization.  Even if not used, domain and trademark ownership can provide benefits, e.g., as a high-return investment or strategic denial of use (e.g., Abbvie purchased "biosimilars.com" from me 9 years ago and has never used it).  There will be no better top-level industry-defining IP available, e.g., the only potential competition, "pharma.com," is tainted, held by Purdue Pharma and part of its bankruptcy proceedings (and otherwise, who wants to be "pharma" vs. "biopharma?")

To perhaps put the current value of this IP in some context, the 'closest' (industry top-end-type) published domain sales (in current $) include "drugs.com" which sold for >$1.2 million in 1999; "pharmacy.com" for $2.9 million in 2008 and; Rx.com for $1 million in 2019.  These BIOPHARMA domains surely have more and broader utility and value than such legacy 'drug' and 'pharmaceutical' transactional (all used for online prescription sales) domains.  Good "brandable" (blank slate) single word .com domains now commonly sell for this much, often more.  In contrast, "BIOPHARMA" is a truly exemplary established single word industry-defining brand with the highest value and good will among all industries.  Besides industry response to Covid-19, this good will and positive image has been assisted by >1.5 decades of pharmaceutical industry promotion redefining and (re)branding the industry as "biopharmaceutical" (including PhRMA annually spending a good portion of its multi-$100s million budget, e.g., the multi-year "GoBoldly" campaign).
Biopharma.com has received a "fair market" appraisal of $1,000,000 (without the trademark; for the domain investor/reseller, not the end-user market) from AccurateAppraisals.com [M. Mann, #1 owner of domains, >300,000]. 

Bottom Line:  'BIOPHARMA' is simply the top-most and best domain name, brand, trademark, corporate identity, etc. for the world's most important, high tech, profitable and image-conscious industry!  "BIOPHARMA" has replaced (or is fast replacing) "pharma(ceutical)" and "drug," particularly when seeking to project a positive, high (bio)tech, etc. image.  Biopharma.com and .org combined with the BIOPHARMA® trademark are truly dominant and enviable top-level industry-defining IP and branding opportunities - embodying the modern biopharmaceutical industry and the inestimable good will it has earned.